Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Quizartinib in patients with Acute Myeloid Leukemia.

The Republic of Ireland's Health Service Executive (HSE) has approved quizartinib as a treatment option for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.

This statement is based on a regulatory approval from the Health Service Executive:

As a monotherapy for the maintenance treatment of adult patients with FLT3-ITD mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.

Citation

Quizartinib Maintenance Therapy, 2026, version number 2, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7019/888_Quizartinib_Maintenance.pdf

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2025-02-01	Health Service Executive	Indication approved for reimbursement.